TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A retrospective review of 60 psychiatric patients found that symptom scores improved after they added L-methylfolate to existing treatment, with the largest measured change in executive function. The non-randomized study cannot show that L-methylfolate caused the gains, and researchers said controlled studies are needed.
A retrospective review of 60 psychiatric patients found that adding L-methylfolate to existing treatment was associated with lower symptom scores, with the largest measured improvement in executive function. The findings, presented at the Neuroscience Education Institute (NEI) Fall Congress, describe an association in routine care—not proof that the supplement caused the changes.
Joel Young, MD, of MedaData and the Rochester Center for Behavioral Medicine in Michigan, and colleagues examined patient records from 2021 to 2026. Of 131 charts identified for patients treated with Deplin, 60 included visits from both before and during L-methylfolate treatment and formed the analysis group. The researchers used a within-patient interrupted time-series design to compare recorded scores over time.
Across measures, the researchers reported an average incremental reduction in overall symptom burden of 0.14 standard deviations (95% confidence interval 0.08 to 0.20 in the direction of improvement; P<0.0001). The pooled outcome combined the ADHD Symptom and Side Effect Tracking scale (ASSET), the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7). The report described improvement on each scale, though the anxiety analysis included only 28 patients because the GAD-7 was added to clinic surveys in late 2024.
The largest individual change was on the ASSET executive-function measure among 58 patients, with a paired effect size of 0.50 in the direction of improvement (95% CI 0.23 to 0.77; P=0.0004). Depression scores improved by a paired effect size of 0.30 among 60 patients (P=0.023), while anxiety scores improved by 0.39 among 28 patients (P=0.048). These are within-patient score changes; they do not by themselves establish clinical benefit for every patient.
Executive Function Led the Score Changes
The findings add routine-practice data on patients already receiving psychiatric treatment, a group for whom the authors said the incremental benefit of adding L-methylfolate has not been well characterized. The prominence of the executive-function result may help shape questions for future research, but it should not be read as evidence that the treatment improves day-to-day functioning. The study measured symptom scales, and whether score changes translated into meaningful changes in patients’ lives remains unknown.
The researchers also found that improvement was more pronounced among patients with more medication classes in their pre-L-methylfolate regimens. Each additional prior medication class was associated with a further 0.118-standard-deviation improvement in the model (P=0.005). That pattern may help identify questions about which patients could benefit, but it does not establish that people with more prior medications will respond better.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells, Pair
BowFlex Results Series 552 SelectTech Adjustable Dumbbell
Blueair Blue Pure 211i Max Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
How the Clinic Records Were Compared
L-methylfolate is the biologically active form of folate, or vitamin B9. The report describes Deplin as a prescription medical food intended for dietary management of suboptimal folate levels in patients with depression and schizophrenia, under medical supervision. The authors noted that earlier clinical research had examined adjunctive L-methylfolate for patients whose depression had not fully responded to standard antidepressants.
This report took a different approach by reviewing records from everyday psychiatric practice and tracking depression, anxiety and executive-function scores before and during treatment. It also reported significant changes in vegetative, somatic and behavioral dimensions, with no assessed side-effect domains worsening significantly. Those results come from the same observational dataset and should be interpreted alongside its limitations.
An exploratory analysis of 23 patients taking stimulants found that dose trajectories shifted from an increase of 3.4 to a decrease of 2.5 milligram-equivalents per year after L-methylfolate began (P=0.0004); the baseline median dose was 26 milligram-equivalents. The authors identified this as an exploratory outcome outside Deplin’s approved dietary-management labeling. The analysis does not establish that L-methylfolate caused a change in stimulant dosing.
“Patients’ executive-function scores showed the largest and earliest change, with depression and anxiety improving more gradually.”
— Richard Powell, PhD, JD, study co-author, speaking to MedPage Today
Cause and Clinical Benefit Remain Unclear
The study was observational and non-randomized, with no comparison group that could establish what would have happened to similar patients without L-methylfolate. The authors said regression to the mean—symptoms improving after treatment starts during a period of active symptoms—is an alternative explanation. Confounding by the reasons clinicians chose the treatment, as well as changes to other medications during the study period, also cannot be ruled out.
All reported P-values were nominal, with no adjustment for multiple comparisons, so the findings across several measures and secondary analyses require caution. The study also drew on a small, demographically limited cohort: the chart review reported that 97.7% of participants were white and 1.5% were Hispanic or Latino. The report does not establish how well results apply to other patient groups.
It remains unclear how much of the observed change, if any, was attributable specifically to L-methylfolate, whether the changes lasted, or whether they translated into better everyday functioning. The smaller anxiety sample and exploratory stimulant-dose analysis add further limits to interpreting those results.
Controlled Studies Needed to Test the Link
The study authors said controlled research is needed to clarify how much of the improvement was attributable to L-methylfolate. A comparison with patients receiving standard care without the add-on, along with more diverse and larger participant groups, could help address the limits of this chart review. Further research would also need to assess whether score changes correspond to meaningful daily-life outcomes and how they develop over time.
No specific follow-up trial or timetable was provided in the report. For now, the findings offer an observational signal for further investigation rather than a definitive estimate of treatment effect. Powell said clinicians should continue asking about persistent symptoms and how patients are managing day to day, while describing L-methylfolate as an option to consider for appropriate patients with an incomplete response to depression treatment.
Key Questions
What did the study find?
In records from 60 psychiatric patients, symptom scores were lower during L-methylfolate treatment than before it. The largest measured change was on an executive-function scale. Because the study was observational, it cannot show that L-methylfolate caused the changes.
Was the study a clinical trial?
No. Researchers conducted a retrospective chart review using patient records from routine care. It was not randomized and did not include a control group.
How many patients were included in the anxiety analysis?
The anxiety measure, GAD-7, was available for 28 patients. The clinic added it to its surveys in late 2024, so the analysis had fewer patients than the depression and pooled analyses.
Did the study prove L-methylfolate improves executive function?
No. It found an association between treatment and improved scores, but the design cannot separate a treatment effect from other explanations, including regression to the mean or changes in concurrent care. The authors called for controlled research.
What happens next?
The authors said controlled studies are needed to determine how much of the observed improvement was attributable to L-methylfolate and whether score changes correspond to meaningful improvements in daily life. The report did not provide a timetable for further research.
Source: medpagetoday.com
